In antibody-dependent cell-mediated cytotoxicity (ADCC), Fc receptor-bearing effector cells recognize and kill antibody-coated target cells that express tumor or pathogen-specific antigens on their surface. The iLite ADCC product portfolio is based on a reporter gene system and offers a convenient and powerful way of measuring the efficacy of antibodies to elicit ADCC in vitro.
This is achieved by combining a cleverly engineered effector cell that closely resembles the natural FcγRIIIA signal transduction pathway, with homologous target cells and controlled antigen expression (+) or depletion (-). Taken together, our unique iLite ADCC portfolio offers unparalleled sensitivity for each target and system that is truly greater than the sum of its parts.
Each cell line in the iLite ADCC product portfolio, is provided in “assay-ready” format for a rapid and convenient workflow and further reduction in assay variability, enabling their use in antibody screening, characterization, stability and potency studies.
We are continuously expanding the iLite® ADCC portfolio with novel and highly specific target cells and can also accommodate most customers request for using in-house/pre-qualified target cells and support that in a cryopreserved assay ready format.
The activity of many antibody-based therapeutics is mediated in part by their ability to induce ADCC and thereby enhancing the body’s own immune response towards dysfunctional cells.
By analyzing the ADCC activity induced by different drugs or drug candidates, a measure of both drug potency and unwanted side effects can be provided and the suggested ADCC mechanism of the drug candidate can be established.
Another area where ADCC assays are important is in the development of biosimilars. There are extensive regulatory requirements in place for analytical characterization of the innovator drug and its biosimilar.
The iLite ADCC product line is a valuable tool for the whole drug development process. It can be used to measure the ability of a drug to induce ADCC activity in a straightforward, sensitive and reproducible manner.
Traditional methods used to measure ADCC use primary donor peripheral blood mononuclear cells (PBMCs) or purified natural killer (NK) cells that express Fc receptors on their cell surface. The killing of target cells is an endpoint of this pathway activation and these primary cell-based assays are highly variable in response, tedious to prepare and can result in high background readings.
The desire for targeted therapy in, for example, cancer has spurred the development of monoclonal antibodies and many have targeted cell surface-expressed antigens found on tumor cells, due to their relative accessibility and specificity.
To overcome many of the limitations of these traditional methods and meet the need of a more robust and reliable assay, Svar Life Science have developed engineer Effector Cells expressing the FC receptor and a suite of specific positive Target Cell as well as a negative control cell line for a number of targets. These targets cells allow screening for specific as wells as unspecific activation of ADCC, giving added value to each experiment.